What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing
Xenon Pharmaceuticals develops therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions.
XENE - Xenon Pharmaceuticals Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$85.00
DETAILS
HIGH:
$100.00
LOW:
$60.00
MEDIAN:
$89.50
CONSENSUS:
$85.00
UPSIDE:
56.91%
Stock News
Xenon Pharmaceuticals Inc. (XENE) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Xenon Pharmaceuticals Inc. (XENE) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Xenon Pharmaceuticals Q1 Earnings Call Highlights
Xenon Pharmaceuticals NASDAQ: XENE said it is preparing to submit a new drug application to the U.S. Food and Drug Administration in the third quarter of 2026 for azetukalner, its investigational anti-seizure medicine, after reporting positive Phase 3 data in focal onset seizures during the first quarter.
Xenon Pharmaceuticals Inc. (XENE) Q1 2026 Earnings Call Transcript
Xenon Pharmaceuticals Inc. (XENE) Q1 2026 Earnings Call Transcript
Xenon Reports Q1 2026 Financial Results and Provides Business Update
VANCOUVER, British Columbia and BOSTON, MA, May 07, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today reported financial results for the first quarter ended March 31, 2026 and provided a business update.
Xenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026
Polarean highlights 20+ ATS 2026 presentations advancing Xenon MRI as a biomarker platform for trials, treatment response, and pediatric lung disease.
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VANCOUVER, British Columbia and BOSTON, MA, May 01, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to seven new non-officer employees consisting of an aggregate of 25,600 share options and 15,000 restricted share units (RSUs). All of the foregoing share options and RSUs were approved by the Compensation Committee of the Company's Board of Directors with an effective date of April 30, 2026 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
Xenon to Report Q1 2026 Financial Results on May 7, 2026
VANCOUVER, British Columbia and BOSTON, MA, April 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced it will report its first quarter 2026 financial results and provide a business update after the close of U.S. financial markets on Thursday, May 7, 2026.
Xenon's Phase 3 Supports A 'Buy' Despite Its Premium
Xenon Pharmaceuticals Inc.'s bull case improved after X-TOLE2 showed robust focal seizure reduction in a highly refractory patient population. Azetukalner's differentiated Kv7 mechanism, once-daily dosing, and no-titration profile may help its future adoption, especially for polytreated epilepsy patients. XENE plans its NDA submission in Q3 2026, which would be a key transition toward potential commercialization and revenues.
Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting
Azetukalner data show significant reductions in seizure frequency across weekly, monthly and multi-year time points X-TOLE2 data featured in Late-breaking Science session show 53. 2% reduction in monthly seizure frequency in 25 mg group vs. 10. 4% for placebo and increasing rates of 100% seizure reduction over time during 12-week double-blind period Long-term data from the ongoing X-TOLE OLE study at 48 months show nearly 40% of participants achieving at least 12 months of seizure freedom and one in four participants achieving at least 24 months of seizure freedom Real-world data reinforce the value of anti-seizure medications that do not require titration to reduce stress and simplify focal seizure management for both patients and physicians VANCOUVER, British Columbia and BOSTON, MA, April 19, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc.
Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting
VANCOUVER, British Columbia and BOSTON, MA, April 19, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today presented positive data from the Phase 3 X-TOLE2 study highlighting the efficacy and safety of azetukalner in focal onset seizures (FOS) at the American Academy of Neurology (AAN) Annual Meeting, taking place April 18-22, 2026 in Chicago, Illinois. Xenon is also presenting data at the AAN meeting that reinforce the significant opportunity for azetukalner in epilepsy, including 48-month data from the ongoing X-TOLE open-label extension (OLE) study, as well as real-world data reinforcing the potential value that no-titration options like azetukalner would bring to epilepsy management. Azetukalner (AZK) is a novel, potent, KV7 potassium channel opener currently in clinical development for epilepsy and depression.
Xenon to Present at Upcoming Investor Conferences
VANCOUVER, British Columbia and BOSTON, MA, April 15, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at four upcoming investor conferences in the second quarter of 2026.
Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting
Five abstracts accepted including Late-breaking Science oral and poster presentations of Phase 3 X-TOLE2 study results for azetukalner in focal onset seizures Poster presentations also include long-term efficacy and safety data from X-TOLE open-label extension study of azetukalner, as well as real-world data regarding the burden of titration and need for no-titration options in epilepsy VANCOUVER, British Columbia and BOSTON, MA, April 07, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced multiple presentations at the upcoming American Academy of Neurology (AAN) Annual Meeting, taking place April 18-22, 2026 in Chicago, Illinois. Five abstracts will be presented, including a Late-breaking Science oral and poster presentation of the topline Phase 3 X-TOLE2 study results for azetukalner in focal onset seizures (FOS), as well as a poster presentation of long-term 48-month azetukalner data from the X-TOLE open label extension study.
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE)
Xenon Pharmaceuticals Inc. (NASDAQ: XENE - Get Free Report) was the recipient of unusually large options trading on Wednesday. Traders bought 4,063 put options on the stock. This is an increase of 2,362% compared to the average volume of 165 put options. Xenon Pharmaceuticals Price Performance Shares of Xenon Pharmaceuticals stock opened at $56.69 on Thursday.
Xenon Pharma Stock Up 55% as Insider Sells $78K in Shares. Here's What Investors Should Know
The chief medical officer of Xenon Pharmaceuticals directly sold 1,410 common shares for a transaction value of $78,000 on March 13, 2026. This sale represented 16.63% of his direct common stock holdings prior to the transaction, reducing his direct position from 8,479 to 7,069 shares.
Xenon Pharmaceuticals Stock Soars 20% in 3 Months: Here's Why
XENE shares gain 20% in 3 months as positive phase III data for epilepsy drug azetukalner and pipeline progress boost outlook and investor confidence.
Xenon Pharmaceuticals Inc. $XENE Shares Sold by Bamco Inc. NY
Bamco Inc. NY reduced its stake in Xenon Pharmaceuticals Inc. (NASDAQ: XENE) by 46.4% during the undefined quarter, according to the company in its most recent filing with the SEC. The fund owned 30,000 shares of the biopharmaceutical company's stock after selling 26,000 shares during the quarter. Bamco Inc. NY's holdings in Xenon
This Fund Has a $200 Million Bet on a Biotech Stock Up 30% in Days After Phase 3 Breakthrough
Driehaus Capital Management increased its XENE stake by 369,577 shares in the fourth quarter; the estimated transaction value was $15.52 million. Meanwhile, the quarter-end position value rose by $36.03 million, reflecting both trading and price appreciation.
Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares
VANCOUVER, British Columbia and BOSTON, MA, March 12, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced the closing of its previously announced underwritten public offering of 12,236,843 common shares, which includes 1,710,526 shares sold upon the full exercise of the underwriters' option to purchase additional shares, and pre-funded warrants to purchase up to 877,194 common shares. The common shares were offered at a public offering price of $57.00 per common share, and the pre-funded warrants were offered at a price of $56.9999 per pre-funded warrant, with each pre-funded warrant having an exercise price of $0.0001. The aggregate gross proceeds to Xenon from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Xenon, were approximately $747.5 million.
Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering
VANCOUVER, British Columbia and BOSTON, March 10, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced the pricing of its upsized underwritten public offering of 10,526,317 common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 877,194 common shares pursuant to its existing shelf registration statement. The common shares are being offered at a public offering price of $57.00 per common share and the pre-funded warrants are being offered at a price of $56.9999 per pre-funded warrant. The gross proceeds to Xenon from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Xenon, are expected to be approximately $650.0 million. In addition, Xenon has granted to the underwriters of the offering an option for a period of 30 days to purchase up to an additional 1,710,526 common shares at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about March 12, 2026, subject to the satisfaction of customary closing conditions.
Price Targets
Xenon Pharmaceuticals price target raised to $69 from $68 at Wells Fargo
$69.00
(was $56.44)
Benjamin Burnett
·
Wells Fargo
Xenon Pharmaceuticals price target lowered to $78 from $80 at Needham
$78.00
(was $56.55)
Serge Belanger
·
Needham
Xenon Pharmaceuticals price target raised to $90 from $56 at Deutsche Bank
$90.00
(was $60.61)
Deutsche Bank
Xenon Pharmaceuticals price target raised to $80 from $59 at RBC Capital
$80.00
(was $62.76)
RBC Capital
Xenon Pharmaceuticals (XENE) PT Raised to $100 at Jefferies
$100.00
(was $62.76)
Andrew Tsai
·
Jefferies
Xenon Pharmaceuticals (XENE) PT Raised to $90 at Guggenheim
$90.00
(was $62.76)
Yatin Suneja
·
Guggenheim
Xenon Pharmaceuticals (XENE) PT Raised to $97 at Baird
$97.00
(was $62.76)
Robert W. Baird
Xenon Pharmaceuticals (XENE) PT Raised to $97 at Baird
$97.00
(was $62.76)
Morgan Stanley
Xenon Pharmaceuticals (XENE) PT Raised to $89 at Stifel
$89.00
(was $61.58)
Paul Matteis
·
Stifel Nicolaus
Jefferies Reiterates Buy Rating on Xenon Pharmaceuticals (XENE): "We see a +50-75% stock move"
$65.00
(was $61.56)
Andrew Tsai
·
Jefferies
Xenon Pharmaceuticals initiated with an Outperform at Wolfe Research
$60.00
(was $42.72)
Wolfe Research
Xenon Pharmaceuticals price target raised to $66 from $60 at Stifel
$66.00
(was $42.43)
Stifel Nicolaus
Xenon Pharmaceuticals price target raised to $58 from $55 at RBC Capital
$58.00
(was $39.63)
RBC Capital
Cantor Fitzgerald Reiterates Overweight Rating on Xenon Pharmaceuticals (XENE)
$55.00
(was $39.78)
Josh Schimmer
·
Cantor Fitzgerald
Xenon Pharmaceuticals price target lowered to $44 from $48 at Wells Fargo
$44.00
(was $41.12)
Benjamin Burnett
·
Wells Fargo
Xenon Pharmaceuticals price target lowered to $42 from $43 at Wedbush
$42.00
(was $37.02)
Wedbush
Xenon Pharmaceuticals resumed with an Outperform at Raymond James
$50.00
(was $39.42)
Danielle Brill
·
Raymond James
Xenon Pharmaceuticals initiated with a Buy at H.C. Wainwright
$53.00
(was $39.37)
Douglas Tsao
·
H.C. Wainwright
Xenon Pharmaceuticals price target lowered to $49 from $50 at Wedbush
$49.00
(was $41.05)
Laura Chico
·
Wedbush
RBC Capital Reiterates Outperform Rating on Xenon Pharmaceuticals (XENE)
$55.00
(was $36.25)
Brian Abrahams
·
RBC Capital